T3D-959

DRUG2 trials

Sponsors

T3D Therapeutics, Inc.

Conditions

Alzheimer's Disease

Phase 1

Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

CompletedNCT02560753

T3D Therapeutics, Inc.Alzheimer's Disease

Start: 2015-07-31End: 2016-06-30Updated: 2018-07-30

Phase 2

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

Not yet recruitingNCT06964230

T3D Therapeutics, Inc.Alzheimer's Disease

Start: 2026-10-26End: 2031-06-30Target: 376Updated: 2025-05-09

Related Papers

The PIONEER Study: A multi‐center, randomized, double‐blind, placebo‐controlled phase 2 trial of the effects of T3D‐959 on safety, cognition, function and plasma biomarkers in mild to moderate Alzheimer’s disease subjects: Rationale and study design

Alzheimer s & Dementia2020-12-013 citations

O1‐12‐04: EFFECTS OF A PPAR DELTA/GAMMA AGONIST, T3D‐959, ON METABOLIC AND COGNITIVE FUNCTIONS IN MILD TO MODERATE ALZHEIMER'S DISEASE SUBJECTS

Alzheimer s & Dementia2018-07-01

Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.

2016-06-0335 citations

T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer’s Disease

Journal of Alzheimer s Disease2016-02-2753 citations